Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 18/20 | 0.66 |
| ▸ | CTSL | P07711 | 11/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3011513 | 0.88 | CTSS (0.70) | CTSSCTSLCTSKPOLBRAB9A | |
| SCHEMBL3011519 | 0.88 | CTSS (0.70) | CTSSCTSLCTSKPOLBRAB9A | |
| SCHEMBL3024585 | 0.80 | CTSS (1.00) | CTSSCTSLCTSK | |
| SCHEMBL3024590 | 0.80 | CTSS (1.00) | CTSSCTSLCTSK | |
| SCHEMBL5844666 | 0.75 | KLK7 (0.55) | CTSSCTSLKLK7POLBRAB9A | |
| SCHEMBL3017458 | 0.75 | CTSS (0.59) | CTSSCTSLCTSK | |
| SCHEMBL3018441 | 0.74 | CTSS (0.47) | CTSSCTSLCTSKKLK7 | |
| SCHEMBL5842376 | 0.72 | CTSS (0.66) | CTSSCTSLCTSK | |
| SCHEMBL5842372 | 0.72 | CTSS (0.66) | CTSSCTSLCTSK | |
| SCHEMBL3023690 | 0.72 | CTSS (1.00) | CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2010-08-12 | — | — | US | disclosed |
| US-7732449-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2010-06-08 | — | — | US | disclosed |
| EP-1658267-B1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-10-14 | — | — | EP | disclosed |
| US-20090137570-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| US-7501408-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2009-03-10 | — | — | US | disclosed |
| US-20080108595-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-7314872-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-01-01 | — | — | US | disclosed |
| EP-1658267-A4 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-08-01 | — | — | EP | disclosed |
| EP-1658267-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2006-05-24 | — | — | EP | disclosed |
| US-20050113356-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-05-26 | — | — | US | disclosed |
| WO-2005034848-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137570-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 11/4885CTSK 9/4885 |
| US-20080108595-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 11/4885CTSK 9/4885 |
| US-20050113356-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 11/4885CTSK 9/4885 |
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSE, CTSV | CTSS 1/4885CTSL 11/4885CTSK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.